- Home
- BIIB vs COHR Comparison
BIIB vs COHR Comparison
Compare BIIB & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- COHR
- Stock Information
- Founded
- BIIB 1978
- COHR 1971
- Country
- BIIB United States
- COHR United States
- Employees
- BIIB N/A
- COHR N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- COHR Electronic Components
- Sector
- BIIB Health Care
- COHR Technology
- Exchange
- BIIB Nasdaq
- COHR Nasdaq
- Market Cap
- BIIB 18.7B
- COHR 18.2B
- IPO Year
- BIIB 1991
- COHR 1987
- Fundamental
- Price
- BIIB $149.61
- COHR $132.71
- Analyst Decision
- BIIB Buy
- COHR Strong Buy
- Analyst Count
- BIIB 25
- COHR 15
- Target Price
- BIIB $183.05
- COHR $118.29
- AVG Volume (30 Days)
- BIIB 1.6M
- COHR 3.4M
- Earning Date
- BIIB 10-30-2025
- COHR 11-05-2025
- Dividend Yield
- BIIB N/A
- COHR N/A
- EPS Growth
- BIIB N/A
- COHR N/A
- EPS
- BIIB 10.97
- COHR N/A
- Revenue
- BIIB $10,065,900,000.00
- COHR $5,810,115,000.00
- Revenue This Year
- BIIB $2.03
- COHR $10.48
- Revenue Next Year
- BIIB N/A
- COHR $11.09
- P/E Ratio
- BIIB $13.64
- COHR N/A
- Revenue Growth
- BIIB 4.77
- COHR 23.42
- 52 Week Low
- BIIB $110.04
- COHR $45.58
- 52 Week High
- BIIB $185.00
- COHR $141.43
- Technical
- Relative Strength Index (RSI)
- BIIB 57.12
- COHR 63.79
- Support Level
- BIIB $148.10
- COHR $112.96
- Resistance Level
- BIIB $151.91
- COHR $141.43
- Average True Range (ATR)
- BIIB 4.19
- COHR 5.50
- MACD
- BIIB -0.10
- COHR 1.57
- Stochastic Oscillator
- BIIB 70.62
- COHR 73.77
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.